Invitrogen

CD134 (OX40) Monoclonal Antibody (ACT35 (ACT-35)), eBioscience™

CD134 (OX40) Antibody in Flow Cytometry (Flow)

FIGURE: 1 / 2

CD134 (OX40) Antibody (14-1347-82) in Flow

Staining of 2-day PHA-L (Product # 00-4977-93)-stimulated normal human peripheral blood cells with 0.125 µg of Mouse IgG1 kappa Isotype Control (Product # 14-4714-85) (blue histogram) or 0.125 µg of CD134 (OX40) Monoclonal Antibody (purple histogram) followed by IgG Polyclonal Antibody, PE (Product # 12-4010-87). Total viable cells were used for analysis, as determined by 7-AAD (Product # 00-6993-50).

Product Image Gallery

Product Details

14-1347-82

Applications

Tested Dilution

Publications

Immunohistochemistry (IHC)

View 2 publications 2 publications

Immunohistochemistry (Paraffin) (IHC (P))

Assay-Dependent

View 1 publication 1 publication

Immunohistochemistry (Frozen) (IHC (F))

Assay-Dependent

Flow Cytometry (Flow)

1 µg/test

View 3 publications 3 publications

Product Specifications

Species Reactivity

Human

Published species

Human

Host/Isotype

Mouse / IgG1, kappa

Class

Monoclonal

Type

Antibody

Clone

ACT35 (ACT-35)

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.5 mg/mL

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.2

Contains

0.09% sodium azide

Storage conditions

4° C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_467479

Product Specific Information

Description: The ACT35 monoclonal antibody reacts with human CD134, also known as OX-40. A member of the TNF receptor superfamily, CD134/OX-40 is a 50 kDa type I membrane glycoprotein expressed by activated T lymphocytes. The interaction of CD134 with OX-40L has been implicated in T cell-dependent humoral response, regulation of primary T cell expansion, survival of T cells, size of the memory T cell pool and regulation of tolerance in the CD4^+ T cell compartment.

Applications Reported: This ACT35 (ACT-35) antibody has been reported for use in flow cytometric analysis, immunohistology staining of frozen tissue sections, and immunohistology staining of paraffin embedded tissue sections.

Applications Tested: The ACT35 (ACT-35) antibody has been tested by flow cytometric analysis of 3-day PHA activated human normal human peripheral blood cells. This can be used at less than or equal to 1 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Purity: Greater than 90%, as determined by SDS-PAGE.

Aggregation: Less than 10%, as determined by HPLC.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

OX40 is a protein receptor found on the surface of T cells, a type of white blood cell that plays a crucial role in the immune system. When activated, OX40 promotes the proliferation and survival of T cells, leading to a stronger immune response against cancer cells and infectious agents. OX40 agonists, which are drugs that activate OX40, have shown promising results in preclinical and clinical studies as a potential immunotherapy for cancer. They can enhance the efficacy of other cancer treatments such as chemotherapy and checkpoint inhibitors, and may also have applications in autoimmune diseases and allergies.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma.

Haematologica

Autio M,Leivonen SK,Brück O,Mustjoki S,Mészáros Jørgensen J,Karjalainen-Lindsberg ML,Beiske K,Holte H,Pellinen T,Leppä S

14-1347 was used in Immunohistochemistry to characterize immunological profiles of diffuse large B-cell lymphoma, and predict the outcome in response to immunochemotherapy.

Mon Mar 01 00:00:00 EST 2021

Changes in circulating exosome molecular profiles following surgery/(chemo)radiotherapy: early detection of response in head and neck cancer patients.

British journal of cancer

Theodoraki MN,Laban S,Jackson EK,Lotfi R,Schuler PJ,Brunner C,Hoffmann TK,Whiteside TL,Hofmann L

Published figure using CD134 (OX40) monoclonal antibody (Product # 14-1347-82) in Flow Cytometry

Wed Dec 01 00:00:00 EST 2021

ICOS⁺ Foxp3⁺ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori.

International journal of cancer

Nagase H,Takeoka T,Urakawa S,Morimoto-Okazawa A,Kawashima A,Iwahori K,Takiguchi S,Nishikawa H,Sato E,Sakaguchi S,Mori M,Doki Y,Wada H

14134782 was used in flow cytometry to establish the T Cell receptor-inducible costimulator as a promising target for direct T regulatory cell-targeting therapeutic agents for gastric cancer

Wed Feb 01 00:00:00 EST 2017

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

NPJ genomic medicine

Reuben A,Spencer CN,Prieto PA,Gopalakrishnan V,Reddy SM,Miller JP,Mao X,De Macedo MP,Chen J,Song X,Jiang H,Chen PL,Beird HC,Garber HR,Roh W,Wani K,Chen E,Haymaker C,Forget MA,Little LD,Gumbs C,Thornton RL,Hudgens CW,Chen WS,Austin-Breneman J,Sloane RS,Nezi L,Cogdill AP,Bernatchez C,Roszik J,Hwu P,Woodman SE,Chin L,Tawbi H,Davies MA,Gershenwald JE,Amaria RN,Glitza IC,Diab A,Patel SP,Hu J,Lee JE,Grimm EA,Tetzlaff MT,Lazar AJ,Wistuba II,Clise-Dwyer K,Carter BW,Zhang J,Futreal PA,Sharma P,Allison JP,Cooper ZA,Wargo JA

14-1347 was used in Immunohistochemistry on paraffin embedded tissues to yield insight into differential therapeutic responses to targeted therapy and immune checkpoint blockade in melanoma, and have key translational implications in the age of precision medicine.

Sat Jan 02 00:00:00 EST 2021

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.

Oncoimmunology

Cooper ZA,Reuben A,Spencer CN,Prieto PA,Austin-Breneman JL,Jiang H,Haymaker C,Gopalakrishnan V,Tetzlaff MT,Frederick DT,Sullivan RJ,Amaria RN,Patel SP,Hwu P,Woodman SE,Glitza IC,Diab A,Vence LM,Rodriguez-Canales J,Parra ER,Wistuba II,Coussens LM,Sharpe AH,Flaherty KT,Gershenwald JE,Chin L,Davies MA,Clise-Dwyer K,Allison JP,Sharma P,Wargo JA

14-1347 was used in Immunohistochemistry to suggest that antitumor immune responses should be assessed when considering therapeutic options for patients with melanoma.

Tue Mar 01 00:00:00 EST 2016

Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma.

International journal of cancer

Voo KS,Foglietta M,Percivalle E,Chu F,Nattamai D,Harline M,Lee ST,Bover L,Lin HY,Baladandayuthapani V,Delgado D,Luong A,Davis RE,Kwak LW,Liu YJ,Neelapu SS

14-1347 was used in Flow cytometry/Cell sorting to assess novel adjuvants that may enhance the efficacy of antitumour immunotherapeutic strategies by inhibiting Tregs.

Mon Dec 15 00:00:00 EST 2014

Bioinformatics

Protein Aliases: ACT35 antigen; ATC35 antigen; CD134; CD134 antigen; lymphoid activation antigene ACT35; OX40 antigen; OX40 cell surface antigen; OX40 homologue; OX40L receptor; TAX transcriptionally-activated glycoprotein 1 receptor; tax-transcriptionally activated glycoprotein 1 receptor; Tumor necrosis factor receptor superfamily member 4; tumor necrosis factor receptor superfamily, member 4

View more View less

Gene Aliases: ACT35; CD134; IMD16; OX40; TNFRSF4; TXGP1L

View more View less

UniProt ID: (Human) P43489

View more View less

Entrez Gene ID: (Human) 7293

View more View less

Function(s)

virus receptor activity tumor necrosis factor-activated receptor activity transmembrane signal receptor

Process(es)

inflammatory response immune response multicellular organism development positive regulation of B cell proliferation response to lipopolysaccharide tumor necrosis factor-mediated signaling pathway T cell proliferation regulation of cell proliferation regulation of apoptotic process positive regulation of MAPK cascade negative regulation of sequence-specific DNA binding transcription factor activity negative regulation of transcription, DNA-templated viral entry into host cell positive regulation of immunoglobulin secretion apoptotic signaling pathway

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more

CD134 (OX40) Monoclonal Antibody (ACT35 (ACT-35)), eBioscience™

CD134 (OX40) Antibody (14-1347-82) in Flow

Product Details

14-1347-82

Immunohistochemistry (IHC)

Immunohistochemistry (Paraffin) (IHC (P))

Immunohistochemistry (Frozen) (IHC (F))

Flow Cytometry (Flow)

Species Reactivity

Published species

Host/Isotype

Class

Type

Clone

Conjugate

Form

Concentration

Purification

Storage buffer

Contains

Storage conditions

Shipping conditions

RRID

Product Specific Information

Target Information

Bioinformatics

Performance Guarantee

We're here to help

Your items have has been added!